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ABSTRACT 
 
The pathogenic mechanisms underlying idiopathic Parkinson's disease (PD) remain 
enigmatic. Recent findings suggest that inflammatory processes are associated with several 
neurodegenerative disorders, including PD. Enhanced expression of the proinflammatory 
cytokine, tumor necrosis factor (TNF)-α, has been found in association with glial cells in the 
substantia nigra of patients with PD. To determine the potential role for TNF-α in PD, we 
examined the effects of the 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP), a 
dopaminergic neurotoxin that mimics some of the key features associated with PD, using 
transgenic mice lacking TNF receptors. Administration of MPTP to wild-type (+/+) mice 
resulted in a time-dependent expression of TNF-α in striatum, which preceded the loss of 
dopaminergic markers and reactive gliosis. In contrast, transgenic mice carrying homozygous 
mutant alleles for both the TNF receptors (TNFR-DKO), but not the individual receptors, 
were completely protected against the dopaminergic neurotoxicity of MPTP. The data 
indicate that the proinflammatory cytokine TNF-α is an obligatory component of 
dopaminergic neurodegeneration. Moreover, because TNF-α is synthesized predominantly by 
microglia and astrocytes, our findings implicate the participation of glial cells in MPTP-
induced neurotoxicity. Similar mechanisms may underlie the etiopathogenesis of PD.      
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he neuropathological basis of Parkinsons disease (PD) involves a progressive 
degeneration of midbrain dopaminergic neurons and their terminals in the striatum (1). 
The etiology of PD remains unknown; however, several mechanisms have been 
proposed to serve as the initiator of the neuronal damage and the subsequent cell death that 
characterize this disorder. These include mitochondrial dysfunction (24), oxidative damage 
(57), excitotoxicity, and α-synuclein deposition (8). In addition to these specific 
mechanisms, inflammatory processes that involve a host of cytokines have been shown to be 
associated with ongoing neuronal degeneration seen in several neurodegenerative diseases, 
including PD (9, 10). Proinflammatory cytokines are known to play a role in mitochondrial 
impairment and oxidative stress; therefore, an inflammatory response may serve as an integral 
feature of the mechanistic underpinnings related to the pathogenesis of PD.  
 
Astrocytes and microglia are thought to play a major role in brain inflammatory responses 
(11, 12). Both of these cell types exhibit a reactive phenotype in association with 
neurodegenerative diseases (1319) as well as in response to neurotoxic insults (2026). 
Recent evidence indicates that brain injury is associated with enhanced expression of 
proinflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-2, 
IL-4, IL-6, transforming growth factor (TGF)-α, and TGF-β1 (2730). Indeed, an elevation in 
these proinflammatory cytokines has been linked to neurodegenerative disorders such as PD 
(14, 31), Alzheimers disease (32, 33), multiple sclerosis (34), and stroke (35), conditions also 
associated with activation of microglia and astroglia. Thus, ample evidence exists to implicate 
cytokines as participants in the pathological processes underlying both neuronal and glial 
responses associated with PD and other degenerative diseases of the central nervous system 
(CNS).  
 
Of the cytokines associated with PD, TNF-α appears to be the most strongly implicated. TNF-
α is known to induce generation of reactive oxygen intermediates associated with necrotic 
cell death (36), and it also induces changes in mitochondrial ultrastructure and function (37, 
38). Both of these damage mechanisms have been implicated in PD. Moreover, significant 
increases in the expression of TNF-α and its receptors have been reported in the caudate and 
putamen of postmortem brain samples from patients with PD (14, 39, 40). More recently, a 
polymorphism of the TNF gene in patients with PD has been associated with the early onset 
of the disease, suggesting a toxic role for TNF (41). To determine whether TNF-α may be 
involved in the pathogenesis of PD, we examined the effects of the dopaminergic neurotoxin, 
MPTP, in mice lacking the receptors for TNF.  
 
MATERIALS AND METHODS 
 
Chemicals and reagents 
 
MPTP-HCl was obtained from Aldrich (Milwaukee, WI). Solutions of 1-methyl-4-phenyl-
1,2,3,4-tetrahydropyridine (MPTP), calculated as free-base, were prepared fresh in isotonic 
saline. Purified bovine GFAP was purchased from American Research Products (Belmont, 
MA). Mouse anti-GFAP monoclonal antibody (clone G-A-5) was obtained from Chemicon 
International (Temecula, CA). Rabbit anti-cow GFAP polyclonal antibody was obtained from 
Dako Corporation (Carpenteria, CA). Mouse anti-rat TH monoclonal antibody and rabbit anti-
rat TH polyclonal antibody were procured from Calbiochem-Novabiochem (San Diego, CA). 
Alkaline phosphatase conjugated anti-mouse IgG was obtained from Jackson 
ImmunoResearch Laboratories (West Grove, PA). Horseradish peroxidase conjugated anti-
rabbit IgG and ECL immunoblotting substrate were purchased from Amersham Pharmacia 
Biotech (Piscataway, NJ). Horseradish peroxidase conjugated anti-mouse IgG and the 
fluorogenic peroxidase substrate, Quantablu, were purchased from Pierce (Rockford, IL). 
Alkaline phosphatase substrate, p-nitrophenyl phosphate, was obtained from Bio-Rad 
(Hercules, CA). Anti-rabbit IgG fluorescent kit, anti-mouse IgG fluorescent kit, Vectashield, 
and antigen unmasking solution were obtained from Vector Laboratories (Burlingame, CA). 
AMV reverse transcriptase and Taq DNA polymerase were procured from Promega 
(Madison, WI). Nitrocellulose membranes were purchased from Schleicher & Schuell (Keene, 
NH). All other chemicals and reagents were of analytical grade and were purchased from 
Sigma (St. Louis, MO) 
  
Animals 
 
All animal experiments were carried out in accordance with CDC and NRC guidelines for 
Care and Use of Laboratory Animals. Male mice aged 46 months (2835 g) were used in all 
experiments. Mice carrying homozygous mutant alleles for TNF receptors (TNFR1, TNFR2, 
or TNFR1/TNFR2) were maintained on a C57BL/6J background. The TNFR knockout mice 
and wild-type C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME) were housed in a 
temperature- (22 ± 2°C) and humidity-controlled (3040%) colony room maintained on a 12-
h light/12-h dark cycle. Animals were allowed ad libitum access to chow and water. Mice 
were administered a single dose of MPTP (12.5 mg/kg, s.c.) or vehicle (saline) alone. Animals 
were killed at various time intervals (148 h postdosing) by cervical dislocation and 
decapitated, and brains were rapidly removed and placed on a cold plate. The striatum from 
both hemispheres was dissected free hand. Striatal tissues from the left hemisphere were used 
for extraction of RNA or estimation of dopamine, and those from the right hemisphere were 
used for analysis of specific proteins. For histopathological assessment, brains were post-
perfusion fixed in 4% paraformaldehyde before cutting sagittal sections of the whole brain or 
coronal sections at the level of striatum. 
 
RNA isolation, cDNA synthesis, and polymer chain reaction (PCR) amplification 
 
Total RNA from striatum (pooled from two animals) was isolated by acid guanidinium 
thiocyanate:phenol:chloroform extraction method (42). DNase treated RNA (1 µg) was 
subjected to first-strand synthesis at 42°C for 60 min in a 20-µl reaction mixture containing 
15 U of avian myeloblastosis virus (AMV) reverse transcriptase and 0.5 µg oligo (dT)15 
primer. At the end of the incubation period, the samples were maintained at 94°C for 5 min 
and then placed on ice to inactivate the enzyme. The cDNA (25 µl) was amplified by 2740 
PCR cycles in a 50-µl reaction containing 1.25 U of Taq polymerase and 1050 pmol of 
template-specific primers for TNF-α, GFAP, and β-actin. The primer sequences were as 
follows: TNF-α, 5'-ATG AGC ACA GAA AGC ATG ATC-3' and 5'-CAG AGC AAT GAC 
TCC AAA GTA-3' (704 bp; ref 43); GFAP, 5'-CGA AGC TAA CGA CTA TCG CC-3' and 
5'-TCA CAT CAC CAC GTC CTT GT-3' (462 bp); β-actin, 5'-AGG CAT TGT GAT GGA 
CTC CG-3' and 5'-AGT GAT GAC CTG GCC GTC AG-3' (300 bp). The thermal cycle 
profile was 1 min at 94°C, 1 min at 58°C, and 1 min at 72°C, followed by a final 7-min 
elongation cycle. A portion (15 µl) of the PCR mixture was subjected to electrophoresis on a 
2% agarose gel containing ethidium bromide. Gels were visualized in a multi-image light 
cabinet (Alpha Innotech, San Leandro, CA) and documented, and the band intensities were 
analyzed using image analysis software (Scion, Frederick, MD). The experiment was 
performed with two sets (n=2 in each set) of striatal samples, and each set was analyzed by at 
least tow independent reverse transcriptase (RT)-PCR reactions.  
 
Tissue preparation for total and specific protein analysis 
 
Tissues were weighed, homogenized in a cell disrupter (Kontes, Vineland, NJ) with 10 
volumes of hot (9095°C) 1% sodium dodecyl sulfate (SDS), and stored at −75°C until use. 
Total protein concentration in the SDS homogenate was determined by bicinchoninic acid 
(BCA) method (44) using bovine serum albumin as the standard.  
 
GFAP ELISA 
 
GFAP was assayed in accordance with a previously described procedure (45, 46). In brief, a 
rabbit polyclonal antibody to GFAP was coated on the wells of Immulon-2 microtiter plates 
(Dynatech Laboratories, Chantilly, VA).  The SDS homogenates and standards were diluted 
in phosphate-buffered saline (PBS) (pH 7.4) containing 0.5% Triton-X 100 solution (PBS-T). 
After blocking nonspecific binding with 5% nonfat dry milk in PBS, aliquots of the 
homogenate and standards were added to the wells and incubated. Following washes, a mouse 
monoclonal antibody to GFAP was added to "sandwich" the GFAP between the two 
antibodies. An alkaline phosphatase conjugated antibody directed against mouse IgG was then 
added, and a colored reaction product was obtained by subsequent addition of the enzyme 
substrate p-nitrophenol. Quantification was achieved by spectrophotometry of the colored 
reaction product at 405 nm in a microplate reader (Spectra Max Plus) and analyzed with Soft 
Max Pro Plus software (Molecular Devices, Menlo Park, CA). The amount of GFAP in the 
samples was calculated as micrograms GFAP per milligrams total protein.            
 
TH ELISA 
 
TH protein levels were assessed by fluorescence-based ELISA developed in this laboratory 
(J.P. O'Callaghan, unpublished results). A mouse monoclonal antibody to tyrosine 
hydroxylase was coated onto Immulon-4 microtiter plates (Dynatech Laboratories) and 
incubated at 37°C for 1 h. Following appropriate washes with PBS and blocking of 
nonspecific binding with 5% nonfat dry milk in PBS, aliquots of SDS homogenates of 
samples and standards were added to the wells and incubated further for 1 h. A rabbit 
polyclonal antibody was added to capture and sandwich the TH protein, which was then 
detected using a peroxidase-labeled antibody directed against rabbit IgG. Peroxidase activity 
was detected using a fluorogenic substrate, Quantablu (Pierce), that has excitation/emission 
maxima of 325/420 nm. The amount of TH in the samples was calculated as micrograms TH 
per milligrams total protein.                   
              
HPLC determination of dopamine and its metabolites 
 
Dopamine and its metabolites were quantified by high-performance liquid chromatography 
(HPLC) with electrochemical detection (HPLC-EC; Waters, Milford, MA). Tissues were 
homogenized in 300 µl of ice-cold 0.2 M perchloric acid, containing 1 µM 
dihydroxybenzylamine (DHBA) as internal standard, and were centrifuged at 10,000g for 10 
min at 4°C. The supernatant was filtered through a 0.2-µm membrane, and an aliquot (10 µl) 
was injected from a temperature-controlled (4°C) automatic sample injector (Waters 717plus 
Autosampler) connected to a Waters 515 HPLC pump. Catecholamines were separated on a 
C18 reverse-phase column (LC-18 RP; Waters SYMMETRY, 25 cm × 4.6 mm; 5 µm), 
electrochemically detected (Waters 464 Pulsed Electrochemical Detector; range 10 nA, 
potential +0.7 V), and analyzed using Millennium32 Software. The mobile phase (pH 3.0) for 
isocratic separation of dopamine consisted of dibasic sodium phosphate (75 mM), octane 
sulfonic acid (1.7 mM), acetonitrile (10% v/v), and EDTA (25 µm). Flow rate was maintained 
at 1 ml/min. Dopamine, dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) 
standards (0.525 pmoles) were prepared in 0.2 M perchloric acid containing 
dihydroxybenzylamine (DHBA). Recovery of each analyte was adjusted with the internal 
standard and quantified from a standard curve. The levels of dopamine and its metabolites are 
expressed as micrograms per gram wet tissue.  
 
Immunoblot analysis of GFAP and TH 
 
In addition to analysis by ELISA, changes in the expression of TH and GFAP were analyzed 
from immunoblots of these proteins. A linear range for the protein load in the immunoblot 
analysis of these proteins has previously been established in our laboratory (47). Aliquots of 
brain homogenates (13 µg) were diluted in sample buffer, boiled, and loaded on 10% sodium 
dodecyl sulfate-polyacrylamide gels (48). Proteins then were electrophoretically resolved and 
transferred to 0.1-µm nitrocellulose membranes (49). Following transfer, we performed 
immunoblot analysis for TH and GFAP. All steps were carried out at room temperature. In 
brief, membranes were blocked for 1 h in 5% nonfat dry milk prepared in PBS-T, washed (1 × 
15 min; 2 × 5 min) with PBS-T, and incubated with antibodies to TH (rabbit polyclonal, 
1:1000) or GFAP (rabbit polyclonal, 1:500) for 2 h. Following incubation with primary 
antibodies, we washed blots with PBS-T (1 × 15 min; 2 × 5 min) and incubated them with 
anti-rabbit IgG-HRP conjugate (1:2500) for 1 h. Membranes were washed (1 × 15 min; 4 × 5 
min) in PBS-T, and signals detected using a chemiluminescent substrate (Amersham ECL, 
Piscataway, NJ) were captured on an X-ray film (Fuji Medical Systems, Stamford, CT), 
typically by exposure from 10 s to 3 min depending on the signal intensity.     
 
Immunohistochemistry 
 
For histological evaluation, animals (saline or MPTP treated +/+ and TNFR-DKO mice) were 
perfused transcardially with 50 ml of saline followed by freshly prepared and cooled 4% 
phosphate-buffered paraformaldehyde. Brains were postfixed for 24 h in 4% 
paraformaldehyde and bisected into the two hemispheres. The right hemisphere was 
processed in increasing grades of sucrose (1030%), and frozen sections (coronal, 25 µm) at 
the level of striatum were cut on a cryomicrotome (Leica CM3000, Leica Microsystems, 
Deerfield, IL) and mounted on Superfrost plus slides (Fisher Scientific, Pittsburgh, PA). The 
left hemisphere was embedded in paraffin, and sagittal sections of 8 µm were cut on a 
microtome. Paraffin-embedded sagittal sections were deparaffinized, rehydrated, and 
processed for antigen retrieval by using an antigen-unmasking solution (Vector Laboratories). 
Two sets of coronal and sagittal sections were independently stained in each analysis. 
Immunohistochemistry for TH (rabbit polyclonal, 1:1000) and GFAP (rabbit polyclonal, 
1:5000) were performed on corresponding serial sections. In brief, sections were treated with 
10% methanol/hydrogen peroxide solution for 15 min to quench endogenous peroxidase. The 
sections were washed (3 × 5 min) in PBS and then permeabilized in a solution containing 
1.8% L-lysine, 4% normal horse serum, and 0.2% Triton-X-100 in PBS. Primary antibody 
diluted in a solution containing PBS and 4% normal horse serum was then added to the 
sections and incubated overnight at 4°C. Following overnight incubation, sections were 
washed in PBS (3 × 5min) and the corresponding FITC-conjugated secondary antibody 
(1:500) was added and incubated for 2 h at room temperature. Sections were then washed (3 × 
5min) with PBS and mounted in an antifade solution (Vectashield; Vector Laboratories). 
Epifluorescence was visualized in a photomicroscope (Olympus AX70) under blue light (for 
FITC; excitation 460490 nm; emission filter 515 nm; wide band pass), and images were 
captured in TIFF format using a Sony 3CCD color video camera (DXC9000, Sony 
Electronics, New York, NY) and Simple32 software (Compix Imaging Systems, Cranberry 
Township, PA).  
 
Statistical analysis 
 
All analyses were performed using SigmaStat (version 2.03) statistical software. The test of 
significance was performed using ANOVA followed by Student-Newman-Keuls (SNK) test. 
Values were considered statistically significant at 5% level of significance (P<0.05). 
Graphical representations are mean ± SE. 
 
RESULTS 
  
Time course of TNF-α and GFAP mRNA expression following administration of MPTP 
 
Systemic administration of MPTP to wild-type +/+ mice resulted in a time-dependent 
increase in the mRNA expression of TNF-α and GFAP (Fig. 1). TNF-α mRNA was 
detectable as early as 3 h (Fig. 1A) following MPTP in the striatum but was undetectable in 
saline treated controls (Fig. 1A) or in a non-target region, hippocampus (data not shown). 
Southern blot analysis of the PCR amplimer, using a digoxigenin (DIG)-labeled human cDNA 
probe to TNF-α, confirmed the expression of TNF-α mRNA in the striatum (Fig. 1B). TNF-α 
mRNA expression preceded the expression of GFAP mRNA (12 h, Fig. 1C and 1D) and the 
loss of the dopaminergic markers, dopamine, and TH. These findings suggest that processes 
associated with enhanced expression of TNF-α precede neurodegeneration-induced 
astrogliosis.     
 
MPTP-mediated loss of striatal dopamine is abolished in mice lacking TNF receptors 
 
Systemic administration of MPTP to wild-type +/+, TNFR1 /, or TNFR2 / mice resulted 
in a significant loss of striatal dopamine by 70% (P<0.001), 63% (P<0.001), and 41% 
(P<0.05), respectively (Fig. 2A). However, the TNFR-DKO mice were protected against the 
dopamine-depleting effects of MPTP (Fig. 2A). Similarly, marked decreases in levels of 
DOPAC and HVA were observed (data not shown) in wild-type mice and TNFR1 / but not 
among TNFR-DKO mice, findings suggestive of a role for TNF-α in MPTP-induced 
dopaminergic neurotoxicity. 
 
MPTP-mediated loss of striatal TH is abolished in mice lacking TNF receptors  
 
Concurrent with the loss of striatal dopamine, MPTP also decreased striatal TH levels that 
were measured by a fluorescence-based ELISA. Administration of MPTP to wild-type +/+, 
TNFR /, or TNFR2 / mice resulted in 54% (P<0.001), 50% (P<0.001), and 47% (P<0.01) 
decreases in striatal TH levels, respectively, 48 h postdosing (Fig. 2B). However, TNFR-DKO 
mice were completely protected against MPTP-induced changes in the levels of TH (Fig. 2B). 
When striatal TH levels were measured at 6, 12, and 48 h following MPTP, significant loss of 
TH was observed only at time points 12 h and beyond, thereby confirming that TNF-α 
expression preceded the loss of TH (data not shown). Immunoblot analysis of TH revealed 
similar differences between +/+ and TNFR-DKO mice in agreement with the results from TH 
ELISA (data not shown). The normal physiological levels of TH were not altered in either the 
single or double TNF-receptor-deficient mice, suggesting that these genetic manipulations did 
not have a regulatory effect on the expression of TH.       
 
Double knockout of TNF receptors abrogates MPTP-mediated up-regulation of striatal 
GFAP 
 
GFAP was assayed as an index of glial response to neuronal injury. Administration of MPTP 
to wildtype +/+ mice or to mice carrying a mutant allele for either of the TNF receptors 
resulted in upregulation of GFAP gene expression, leading to accumulation of GFAP protein. 
Striatal GFAP mRNA levels increased by 1.7-2.7 fold in each of these groups (P<0.05, Fig. 
2C). By 48 h post-dosing, significant increases in striatal GFAP protein (fourfold over 
respective controls, P<0.001, Fig. 2D) was also observed in these groups of mice. However, 
in mice lacking both the receptors for TNF (TNFR-DKO), no significant upregulation of 
GFAP expression was seen (Figs. 2C&D). The normal physiological levels of GFAP were not 
altered in either the single or double TNF receptor deficient mice, suggesting that these 
genetic manipulations did not have a regulatory effect on the expression of GFAP. Together, 
these results reconfirm the involvement of TNF in the neurotoxicity of MPTP.  
 
Mice deficient in TNF receptors are protected against MPTP-mediated loss of striatal 
TH immunoreactivity and associated reactive gliosis 
 
MPTP treatment resulted in loss of TH immunoreactivity, and it induced astrogliosis in 
wildtype +/+ mice. A marked loss of TH immunoreactivity was observed following 
degeneration of dopaminergic terminals in the striatum (Fig. 3A, left panels). Loss of TH 
immunoreactivity was associated with a concomitant astrogliosis as reflected by an increase 
in GFAP immunostaining (Fig. 3B, left panels). In TNFR-DKO mice, immunostaining for TH 
(Fig. 3A, right panels) and GFAP (Fig. 3B, right panels) further confirmed the 
neuroprotection afforded by the TNFR double receptor knockouts. Immunohistochemical 
evaluation of TH and GFAP substantiated the changes that were observed by ELISA for TH 
and GFAP, respectively.  
 
DISCUSSION 
 
We have demonstrated that enhanced expression of TNF-α is associated with the earliest 
stages of damage in the MPTP model of dopaminergic neurotoxicity. Moreover, using mice 
lacking receptors for TNF, we showed complete protection against MPTP-induced 
neurotoxicity. The early onset of TNF-α expression after MPTP and the neuroprotective 
effect afforded to dopaminergic neurons by TNF receptor deficiency implicate this 
proinflammatory cytokine as a potential upstream effector in the neurodegenerative processes 
underlying PD.  
 
The roles of cytokines in various forms of neurodegenerative disorders are extensively 
documented. Proinflammatory cytokines such as IL-6 and TNF-α are known to be associated 
with the neuropathological effects underlying neurological disorders such as Alzheimers 
disease (33), PD (39), multiple sclerosis (50, 51), and traumatic brain injury (52, 53). These 
cytokines also are expressed following experimentally induced neurodegeneration. For 
example, dopaminergic selective neurotoxins such as 6-hydroxydopamine and MPTP, agents 
commonly used to create animal models of PD, are able to induce expression of TNF-α in the 
nigrostriatal pathway (54). Moreover, enhanced expression of TNF-α has been shown to 
lower tyrosine hydroxylase immunoreactivity in the caudate-putamen (55). Consistent with 
these observations, we found that MPTP was able to induce the expression of striatal TNF-α 
mRNA within 3 h of s.c. administration with a peak increase in expression at 12 h after 
MPTP. This time course of TNF-α mRNA expression preceded the loss of striatal dopamine 
and TH, indices of damage to dopaminergic nerve terminals affected by MPTP (56). The 
effects on TNF-α mRNA also preceded the induction of GFAP mRNA and protein, indices of 
astrogliosis caused by MPTP-induced damage to dopaminergic nerve terminals (56). 
Together, these data suggest that enhanced expression of TNF-α is an early feature of the 
sequence of events associated with degeneration of the nigrostriatal dopaminergic pathway. 
 
The known association of TNF-α expression with neuropathology and our demonstration of 
its early induction in the MPTP model of dopaminergic neurotoxicity are suggestive of a 
participatory role for this cytokine in damage to the nigrostriatal dopaminergic pathway. We 
explored this possibility by using mice deficient in TNF receptors. Our results demonstrate 
that the effects of MPTP on multiple indices of damage to dopaminergic nerve terminals can 
be completely blocked in the TNFR-DKO mice, but not in the individual receptor-deficient 
mice. These results strongly implicate TNF-α and its receptors as mediators of damage to 
dopaminergic nerve terminals caused by MPTP. Moreover, these data suggest that 
neuroprotection requires the absence or deficiency of both TNF receptor subtypes. Earlier 
studies suggested that TNFR1 was the essential subtype for TNF-induced modulation of gene 
expression and cytotoxicity (57). Nevertheless, TNFR2 alone is capable of signaling cell 
death (58). Although each TNF receptor was thought to mediate distinct cellular responses, 
more recent studies provided evidence for receptor cooperation in mediating the cytocidal 
effect of TNF-α (59). Thus, inhibition or deficiency of either of the receptors alone may not 
prevent detrimental aspects of TNF-α-mediated events. Our observations are in concordance 
with these findings. 
  
Our results stand in contrast to the results of an earlier study, in which lack of TNF receptors 
aggravated hippocampal excitotoxic injury (60). This disparity in the role of TNF-α in 
neurotoxicity may be explained by taking into consideration the region-specific effects of this 
cytokine. Because TNF-α is predominantly expressed by microglia (6163) and astrocytes 
(6365) in the CNS, differences in the intrinsic characteristics among these glial cell types 
and in the glial-neuronal interactions in specific brain regions may contribute to the altered 
responses to toxic insults. For example, a previous study demonstrated reduction of striatal 
excitotoxic injury by a TNF-α inhibitor, whereas exacerbation of the injury occurred in the 
hippocampus (66).   
 
Activation of microglia and the induction of astrogliosis can be modulated by cytokines, and 
these cellular responses to brain injury often have been linked to inflammatory changes in the 
CNS (12, 67, 68). Our results demonstrate that induction of TNF-α mRNA precedes the 
induction of GFAP mRNA after MPTP. This time-effect relationship is consistent with the 
time course for microglial activation after MPTP (69). Indeed, activated microglia are known 
to express proinflammatory cytokines, including TNF-α. Because the results of the 
experiments with the TNF-receptor-deficient mice are suggestive of an obligatory role of 
TNF-α in MPTP-induced neurotoxicity, TNF-α producing microglia appear to be the most 
likely cellular effectors in the damage cascade. Consistent with this notion is the fact 
microglia are capable of producing damaging reactive nitrogen and oxygen intermediates 
(70).  
 
Oxidative stress has been implicated in a variety of neurological diseases states, including PD 
(71, 72). Mitochondrial dysfunction also is known to be involved in several 
neurodegenerative disorders, including PD (73), as well as in neurotoxin-mediated 
neurodegeneration (7479). Oxidative stress and mitochondrial dysfunction are the major 
factors that have been implicated in the dopaminergic neurotoxicity of MPTP. The early 
induction of striatal TNF-α observed in this study that precedes the generation of reactive 
oxygen species (ROS) following MPTP (76) is suggestive of the involvement of TNF-α in 
inducing oxidative stress. Indeed, ROS are generated through the signaling cascade mediated 
by TNF-α (80). Furthermore, mitochondria have been shown to participate in TNF-induced 
cell damage by generating ROS (81). Thus, MPTP-induced oxidative stress and mitochondrial 
dysfunction may be mediated by signaling cascades triggered by TNF-α. Previous 
demonstrations of the presence of TNF receptors on nigrostriatal dopaminergic neurons (14), 
the increased nuclear translocation of NF-κB in dopaminergic neurons (82), and the existence 
of a cytokine/CD23-dependent activation pathway of iNOS and proinflammatory cytokines in 
glial cells (83) in PD strengthen the proposition that TNF-α may be involved in the oxidant 
injury to the dopaminergic neurons in MPTP neurotoxicity as well as in PD.  
 
In summary, our results implicate TNF-α as an obligatory component of dopaminergic 
neurotoxicity caused by MPTP, and they suggest that microglia may serve as the cellular 
effectors of TNF-α-mediated neurodegeneration. The broad implication of these findings is 
that pharmacological modulation of the TNF receptors or intermediates in its signaling 
cascade may provide novel and, perhaps, a mechanistically based approach for the treatment 
of PD. 
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Fig. 1 
 
 
 
Figure 1. 1-Methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP)-mediated expression of striatal tumor necrosis 
factor (TNF)-α mRNA precedes the induction of GFAP mRNA. Wild-type +/+ mice were administered either saline 
or MPTP (12.5 mg/kg, s.c.) and killed at various time intervals (1–24 h). A) TNF-α mRNA expression was analyzed by 
reverse transcriptase-polymer chain reaction (RT-PCR). B) Southern blot analysis of the PCR amplimer with a 
digoxigenin-labeled human cDNA probe to TNF-α and detection with CDP-Star confirmed the specificity and size of the 
amplified product. C) GFAP mRNA expression was analyzed by RT-PCR. D) Northern blot analysis with a digoxigenin-
labeled mouse cDNA probe to GFAP and detection with CDP-Star confirmed the expression of GFAP mRNA.Values are 
mean ±SE (n = 4 per time point). *Significantly different from saline-treated controls (P<0.01). Newman-Keuls pair-wise 
comparisons were used for post hoc statistical analysis. 
Fig. 2 
 
 
 
Figure 2. MPTP-mediated loss of striatal dopaminergic markers and induction of astrogliosis are abolished in 
TNFR-DKO mice. Wild-type +/+, TNFR1–/–, TNFR2–/–, and TNFR-DKO mice were administered either saline or 
MPTP (12.5 mg/kg, s.c.) and killed at 12 h or 48 h after treatment. A) Striatal levels of dopamine were quantified by high-
performance liquid chromatography with electrochemical detection, 12 h postdosing (n = 5 per group). B) Striatal TH 
protein levels 48 h postdosing was quantified by ELISA (n = 8–10 per group). C) Striatal GFAP mRNA expression was 
analyzed by RT-PCR, 48 h posttreatment with MPTP (n = 4 per group). D) Striatal GFAP protein levels 48 h 
posttreatment were quantified by ELISA (n = 8-10 per group). Values are mean ±SE.  *Significantly different from 
respective saline-treated controls (P<0.01). Newman-Keuls pair-wise comparisons were used for post hoc statistical 
analysis. 
Fig. 3 
 
                     
 
Figure 3. MPTP-mediated loss of TH immunoreactivity and increase in GFAP immunoreactivity are abolished in 
TNFR-DKO mice. Wild-type +/+, TNFR1–/–, TNFR2 –/–, and TNFR-DKO mice were administered either saline or 
MPTP (12.5 mg/kg, s.c.) and killed 48 h later. Two sets of coronal or sagittal serial sections were independently stained in 
each analysis for TH (polyclonal, 1:1000) and GFAP (polyclonal, 1:5000). A) TH immunoreactivity in striatum showing 
decreased staining in MPTP-treated wild-type +/+ mice and complete protection against MPTP neurotoxicity in TNFR-
DKO mice. B) Concomitant increase in GFAP immunoreactivity (reactive astrogliosis) seen in the same field in wild-type 
+/+ mice is abolished in TNFR-DKO mice. Scale bar, 140 µm.          
